Hot Features
プレミアム
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Neuralstem Inc is a clinical-stage biopharmaceutical company. The company is engaged in research, development, and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. Its technology base has produced three p... Neuralstem Inc is a clinical-stage biopharmaceutical company. The company is engaged in research, development, and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. Its technology base has produced three primary assets: NSI-189 small molecule program, NSI-566 stem cell therapy program and novel and proprietary new chemical entity screening platform. 詳細を表示
RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was...
Letter from Seneca Biopharma's Executive Chairman PR Newswire GERMANTOWN, Md., Sept. 2, 2020 GERMANTOWN, Md., Sept. 2, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a...
Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering PR Newswire GERMANTOWN, Md., May 27, 2020 GERMANTOWN, Md., May 27, 2020 /PRNewswire/ -- Seneca Biopharma, Inc...
Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA PR Newswire GERMANTOWN, Md., Oct. 31, 2019 GERMANTOWN, Md., Oct. 31, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (Nasdaq: CUR), a...
Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases PR Newswire GERMANTOWN, Md., Oct. 30, 2019...
Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit PR Newswire GERMANTOWN, Md., Oct. 28, 2019 GERMANTOWN, Md., Oct. 28, 2019 /PRNewswire/...
Neuralstem Becomes Seneca Biopharma PR Newswire GERMANTOWN, Md., Oct. 28, 2019 GERMANTOWN, Md., Oct. 28, 2019 /PRNewswire/ -- Neuralstem, Inc. (NASDAQ:CUR), announces that the company has changed...
Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4) PR Newswire GERMANTOWN, Md., Oct. 3, 2019 GERMANTOWN, Md., Oct. 3, 2019 /PRNewswire/ -- Neuralstem, Inc...
Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients PR Newswire GERMANTOWN, Md., Sept. 24, 2019 GERMANTOWN, Md...
Neuralstem Reports Second Quarter 2019 Fiscal Results PR Newswire GERMANTOWN, Md., Aug. 14, 2019 GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Graniteguy
5分前
BDEZ
5分前
surfer44
6分前
sortagreen
7分前
carlson
7分前
StocktonCA
8分前
carlson
10分前
Lime Time
11分前
janice shell
12分前
jimr1717
12分前
droopyeyes
13分前
Top Penny
14分前
Top Penny
14分前
Preciouslife1
15分前
gitreal
15分前
BakedLangostino
15分前
BakedLangostino
15分前
jimr1717
16分前
Lime Time
16分前
doc2016
17分前
j_iliz
17分前
BDEZ
20分前
MiamiGent
20分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
